ARTV
NasdaqGMArtiva Biotherapeutics, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 21 recent filings. 0 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 20.82K | $9.99 | $208,031.76 | 2026-07-29 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 24.94K | $9.93 | $247,693.92 | 2026-07-31 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 41.32K | $9.99 | $412,776.81 | 2026-07-24 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 120.58K | $9.55 | $1,151,558.10 | 2026-07-21 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 84.12K | $9.93 | $835,351.32 | 2026-07-22 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 59.88K | $9.96 | $596,404.80 | 2026-07-23 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 6.52K | $8.94 | $58,306.68 | 2026-07-13 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 152.47K | $8.93 | $1,361,574.96 | 2026-07-16 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 7.88K | $8.95 | $70,543.90 | 2026-07-17 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 15.1K | $8.97 | $135,464.94 | 2026-07-10 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 6.55K | $8.94 | $58,574.88 | 2026-07-13 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 31K | $8.88 | $275,280.00 | 2026-06-25 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 1.88K | $8.98 | $16,846.48 | 2026-06-26 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 391.02K | $8.57 | $3,351,032.83 | 2026-06-12 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 15.41K | $8.99 | $138,571.86 | 2026-06-15 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 124.89K | $8.89 | $1,110,298.77 | 2026-06-16 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 479.04K | $6.91 | $3,310,159.49 | 2026-06-09 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 103 | $7.00 | $721.00 | 2026-06-10 |
RA CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy (open market) | 548.58K | $7.91 | $4,339,267.80 | 2026-06-11 |
GC Corp. 10% Owner | Buy (open market) | 1.09M | $11.52 | $12,499,994.88 | 2026-05-11 |
GC Corp. 10% Owner | Buy (open market) | 347.22K | $11.52 | $3,999,997.44 | 2026-05-11 |
Source: SEC EDGAR Forms 4/4A (CIK 1817241). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
Artiva Biotherapeutics Stock Hub: $ARTV, AlloNK, FDA RMAT and the Phase 3 Rheumatoid Arthritis Path https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/
#INSIDERS $ARTV 10% owner RA Capital bought 264,586 shares at $9.40 - $10 worth approximately $2.6 mln (transaction dates 7/21-7/23). ENR 10% owner bought 120,000 shares at $19.64 - $21.05 worth approximately $2.4 mln (transaction dates 7/21-7/22). $NPWR 10% owner sold 209,142 shares worth approximately $319K (transaction dates 7/21-7/23).
$ARTV Interesting form 4s here. Bully!
$ARTV another big buy from this director. he's been buying alot since mid June. 4th buy. ARTV Artiva Biotherapeutics: Shah Rajeev M. (Director, 10%+) Buys 264,586 Shares @ Average Price of $9.76 (Form 4)
$ARTV Insider purchase: https://filingtracker.ai/filing/1315082/0001231919-26-000791?doc=form4-07242026_010725.xml
$ARTV RA Capital trying to buy every share? Now over 17M.
$ARTV after da final MNDY 🐑 🎁 out of the tightness da huckleberries will be below da $$$$ ENTA 🐒🍌🧠⏰♾️
$ARTV Google finance says : For Artiva Biotherapeutics Inc (NASDAQ:ARTV), analysts maintain a bullish outlook for the end of 2026, with an average price target of approximately $39.00. Forecasts from major firms range from a low of $23.00 to a high of $41.00. As of July 17, 2026, the stock was trading at $9.76, meaning the consensus target represents a potential upside of nearly 300%.
$ARTV nice close
$ARTV Buyout very probable by EOY.. maybe two buyouts. And you think.. Huh? Their RA trial is a lay up. The 3 ptr will be their 2nd target. Their advantage: Efficacy with virtually no toxicity.
$ARTV Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://marketwirenews.com/stock/artv/news/artiva-biotherapeutics-announces-new-employee-induce-6819930485705014.html?utm_source=stocktwits
$ARTV New to ARTV , never catch a falling knife? Did i? .....bought some at USD 9.22 to start....
Latest news
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Artiva Biotherapeutics Reports Positive AlloNK Data Across Autoimmune Diseases at EULAR 2026
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics Appoints Diego Miralles as President
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Sector Update: Healthcare Stocks Steady Pre-Bell Friday
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.